At the ASCO 2019 annual meeting, Hamid Emamekhoo discusses the efficacy and safety of the combination of nivolumab plus ipilimumab in patients with symptomatic melanoma brain metastases (CheckMate 204) and how these findings will likely impact the management of the disease.
1. What are the limitations of current treatment options for patients with metastatic renal cell carcinoma (mRCC) brain metastases? (0:03)
2. What were the findings of CheckMate 920 in patients with mRCC brain metastases? (0:37)
3. What was the anti-tumour activity of ipilimumab plus nivolumab in these patients? (3:11)
4. How are these findings likely to impact on the clinical management of mRCC brain metastases? (4:01)
Speaker disclosure: Hamid Emamekhoo has nothing to disclosure in relation to this video interview.
Filmed at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting, Chicago, IL, USA.
Share this Video
Related Videos In Renal Cancer
Yann-Alexandre Vano, ESMO 2020 – Nivolumab and Ipilimumab or VEGFR Tyrosine Kinase Inhibitor in Naive Metastatic Kidney Cancer: The BIONIKK Trial
Dr Yann-Alexandre Vano joins touchONCOLOGY to discuss the role of personalization of treatment in kidney cancer, and the major findings from the BIONIKK trial investigating nivolumab and ipilimumab as a first-line therapy for patients with kidney cancer. The late-breaking abstract ‘Results from the phase 2 BIOmarker driven trial with Nivolumab (N) and Ipilimumab or VEGFR […]
Lorenza Rimassa, ESMO 2019 – COSMIC-312 study in hepatocellular carcinoma
We joined Lorenza Rimassa (Humanitas Research Hospital-IRCCS) at ESMO 2019 to discuss the Phase III COSMIC-312 study (NCT03755791) of cabozantinib plus atezolizumab versus sorafenib in patients with advanced hepatocellular carcinoma. Questions 1. What are the limitations of current first-line treatment strategies for advanced hepatocellular carcinoma? (0:05) 2. What is the rationale for combining cabozantinib with […]
James Brugarolas, ASCO 2019 – Advances in sarcomatoid RCC
At the ASCO 2019 annual meeting, James Brugarolas discusses sarcomatoid renal cell carcinoma, the current challenges and the advances that are defining a new treatment paradigm. Questions 1. What is sarcomatoid renal cell carcinoma (RCC) and what is its prognosis? (0:04) 2. What are the major treatment challenges in sarcomatoid RCC? (0:54) 3. Why is […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!